SCHEMBL3537670

SCHEMBL3537670

CN(c1ccc([N+](=O)[O-])c(N2CCCCC2)c1)S(C)(=O)=O

nearest known ligand 0.58

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 11/20 0.58
MAPT P10636 10/20 0.58
MAPK1 P28482 4/20 0.58
POLB P06746 3/20 0.58
CYP1A2 P05177 3/20 0.55
CYP2C19 P33261 3/20 0.55
L3MBTL1 Q9Y468 1/20 0.55
LMNA P02545 3/20 0.53
SMN1; SMN2 Q16637 3/20 0.51
GAA P10253 2/20 0.51
NPSR1 Q6W5P4 1/20 0.50
CYP2C9 P11712 2/20 0.48
CYP3A4 P08684 1/20 0.48
CYP2D6 P10635 1/20 0.48
MCOLN3 Q8TDD5 1/20 0.48
CSF1R P07333 1/20 0.46
HPGD P15428 1/20 0.46
ALDH1A3 P47895 1/20 0.45

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5104601 0.85 ALDH1A1 (0.62) ALDH1A1MAPTMAPK1POLBCYP1A2
SCHEMBL5097941 0.80 ALDH1A1 (0.56) ALDH1A1MAPTMAPK1POLBCYP1A2
SCHEMBL3534495 0.79 CSF1R (0.52) ALDH1A1MAPTMAPK1POLBCYP1A2
SCHEMBL7515290 0.78 MAPT (0.58) ALDH1A1MAPTMAPK1POLBCYP1A2
SCHEMBL20623078 0.77 ALDH1A1 (0.56) ALDH1A1MAPTMAPK1POLBCYP1A2
SCHEMBL26124496 0.77 HPGD (0.59) ALDH1A1MAPTMAPK1POLBCYP1A2
SCHEMBL20623093 0.75 ALDH1A1 (0.50) ALDH1A1MAPTMAPK1POLBCYP1A2
SCHEMBL3227183 0.75 MAPT (0.68) ALDH1A1MAPTPOLBSMN1; SMN2CYP3A4
SCHEMBL25891601 0.75 ALDH1A1 (0.68) ALDH1A1MAPTMAPK1POLBCYP1A2
SCHEMBL3542062 0.74 CSF1R (0.51) ALDH1A1MAPTL3MBTL1LMNASMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7705042-B2 Class of arylamide compounds useful as inhibitors of c-fms kinase JANSSEN PHARMACEUTICA NV (BE) 2010-04-27 US disclosed
EP-1807407-B1 AROMATIC AMIDES AS INHIBITORS OF C-FMS KINASE JANSSEN PHARMACEUTICA NV (BE) 2009-07-29 EP disclosed
EP-1807407-A1 AROMATIC AMIDES AS INHIBITORS OF C-FMS KINASE JANSSEN PHARMACEUTICA N.V. (BE) 2007-07-18 EP disclosed
US-20060100201-A1 Inhibitors of c-fms kinase JANSSEN PHARMACEUTICA, N.V. (BE) 2006-05-11 US disclosed
WO-2006047504-A1 AROMATIC AMIDES AS INHIBITORS OF C-FMS KINASE JANSSEN PHARMACEUTICA, N.V. (BE) 2006-05-04 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060100201-A1 Inhibitors of c-fms kinase MUSK, FLT3, FES ALDH1A1 4796/4885MAPT 159/4885MAPK1 280/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.